title: Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expression.
abstract: Changes in blood dendritic cell (BDC) counts (CD123(hi)BDC and CD11c(+)BDC) and expression of CD62L, CCR7, and CD49d were analyzed in healthy donors, multiple myeloma (MM), and non-Hodgkin lymphoma (NHL) patients, who received granulocyte-colony stimulating factor (G-CSF) containing peripheral blood stem cell (PBSC) mobilization protocols. Low-dose G-CSF in healthy donors (8-10 microg/kg/d subcutaneously) and high-dose G-CSF in patients (30 microg/kg/d) increased CD123(hi)BDC (2- to 22-fold, mean 3.7 x 10(6)/L-17.7 x 10(6)/L and 1.9 x 10(6)/L-12.0 x 10(6)/L) in healthy donors and MM but decreased CD11c(+)BDC (2- to 10-fold, mean 5.7 x 10(6)/L-1.6 x 10(6)/L) in NHL patients, on the day of apheresis, compared with steady state. After apheresis, CD123(hi)BDC counts remained high, whereas low CD11c(+)BDC counts tended to recover in the following 2-5 days. Down-regulation of CD62L and up-regulation of CCR7 on CD123(hi)BDC were found in most healthy donors and MM patients. CD49d expression was unchanged. Thus, PBSC mobilization may change BDC counts by altering molecules necessary for BDC homing from blood into tissues.
authors.affiliation: Mater Medical Research Institute, South Brisbane, Queensland, Australia.
authors.forename: Slavica
authors.initials: S
authors.lastname: Vuckovic
authors.forename: Min
authors.initials: M
authors.lastname: Kim
authors.forename: Dailal
authors.initials: D
authors.lastname: Khalil
authors.forename: Cameron J
authors.initials: CJ
authors.lastname: Turtle
authors.forename: Georgina V
authors.initials: GV
authors.lastname: Crosbie
authors.forename: Noel
authors.initials: N
authors.lastname: Williams
authors.forename: Len
authors.initials: L
authors.lastname: Brown
authors.forename: Katrina
authors.initials: K
authors.lastname: Williams
authors.forename: Cathryn
authors.initials: C
authors.lastname: Kelly
authors.forename: Penny
authors.initials: P
authors.lastname: Stravos
authors.forename: Robyn
authors.initials: R
authors.lastname: Rodwell
authors.forename: Geoff R
authors.initials: GR
authors.lastname: Hill
authors.forename: Susan
authors.initials: S
authors.lastname: Wright
authors.forename: Kerry
authors.initials: K
authors.lastname: Taylor
authors.forename: Devinder
authors.initials: D
authors.lastname: Gill
authors.forename: Paula
authors.initials: P
authors.lastname: Marlton
authors.forename: Ken
authors.initials: K
authors.lastname: Bradstock
authors.forename: Derek N J
authors.initials: DN
authors.lastname: Hart
mesh_terms: D000328:Adult; D000368:Aged; D001781:Blood Component Removal; D039521:CD11c Antigen / Q000032:analysis; D002452:Cell Count; D003520:Cyclophosphamide / Q000008:administration & dosage; D003713:Dendritic Cells / Q000166:cytology* / Q000276:immunology*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology*; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D053650:Interleukin-3 Receptor alpha Subunit; D019041:L-Selectin / Q000032:analysis*; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000276:immunology; D054400:Receptors, CCR7; D019707:Receptors, Chemokine / Q000032:analysis*; D016185:Receptors, Interleukin-3 / Q000032:analysis*; D020858:Tissue and Organ Harvesting
chemical_list: C515370:CCR7 protein, human; D039521:CD11c Antigen; C115022:IL3RA protein, human; D053650:Interleukin-3 Receptor alpha Subunit; D054400:Receptors, CCR7; D019707:Receptors, Chemokine; D016185:Receptors, Interleukin-3; D019041:L-Selectin; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide